肠道菌群在药源性肝损伤中的作用及其保肝机制的研究进展  

Research progress on the effect of gut microbiota and its hepatoprotective mechanism in drug-induced liver injury

作　　者：缪志敏 赖泳 MIAO Zhimin;LAI Yong(College of Pharmacy and Chemistry,Dali University,Dali 611000,China)

机构地区：[1]大理大学药学与化学学院药理学研究室,云南大理671000

出　　处：《沈阳药科大学学报》2020年第9期847-851,共5页Journal of Shenyang Pharmaceutical University

基　　金：国家自然科学基金资助项目(81360511);云南省教育厅科学研究基金(2019Y0262)。

摘　　要：目的综述肠道菌群在药源性肝损伤中的作用及其保肝机制。方法查阅国内外近几年相关文献,对肠道菌群的保肝机制进行探讨;对肠道菌群在对乙酰氨基酚、一线抗结核药和铁剂所致肝损伤中的作用进行分析归纳总结。结果肠道菌群的保肝机制分为直接保护作用和间接保护作用;在对乙酰氨基酚、一线抗结核药和铁剂所致肝损伤中均能发现肠道菌群结构的改变,某些菌群的丰度大小与肝损伤程度有着密切关联。结论肠道菌群有望成为治疗药源性肝损伤的新靶点。Objective To review the effect of gut microbiota and its hepatoprotective mechanism in drug-induced liver injury.Methods The relevant literatures in recent years at home and abroad were referred to explore the mechanism of hepatoprotective effect of gut microbiota.The effects of gut microbiota in acetaminophen,first-line anti-tuberculosis drugs and iron agent-induced liver injury were analyzed and summarized.Results The hepatoprotective mechanism of gut microbiota could be divided into direct protection and indirect protection.Alteration of the gut microbiota composition was found in acetaminophen,first-line anti-tuberculosis drugs and iron agent-induced liver injury.Conclusion Gut microbiota is expected to become a new target for the treatment of drug-induced liver injury.

关 键 词：肠道菌群 药源性肝损伤 保肝药物 

分 类 号：R96[医药卫生—药理学]